Chris Raymond
Stock Analyst at Raymond James
(2.13)
# 4,928
Out of 4,974 analysts
7
Total ratings
100%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $23.90 | +88.28% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $12.63 | +177.12% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $80.89 | +29.81% | 1 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Strong Buy | $80 | $44.21 | +80.95% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $4.62 | +397.84% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $13.05 | +129.89% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $15.87 | +372.59% | 1 | Sep 3, 2025 |
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $23.90
Upside: +88.28%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $12.63
Upside: +177.12%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $80.89
Upside: +29.81%
Monopar Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $80
Current: $44.21
Upside: +80.95%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $4.62
Upside: +397.84%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $13.05
Upside: +129.89%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $15.87
Upside: +372.59%